NCT04447755: A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 2 Years to 21 Years (Child, Adult)
Location of Metastases: Leptomeningeal Disease
Additional Notes: 
Exclusions: Patients with untreated CNS metastases; Patients with leptomeningeal disease are eligible

Comments are closed.

Up ↑